Photo credit: NCI Center for Cancer Research.
Approach exploits tumor weaknesses when 2 genetic defects are combined. Researchers report that inhibiting a key enzyme caused human cancer cells associated with two major types of breast and ovarian cancer to die and in mouse studies reduced tumor growth.
With advances in genome sequencing, cancer treatments have increasingly sought to leverage the idea of “synthetic lethality,” exploiting cancer-specific genetic defects to identify targets that are uniquely essential to the survival of cancer cells.
Synthetic lethality results when non-lethal mutations in different genes become deadly when combined in cells.
The research team, led by senior study author Richard D...
Read More
Recent Comments